Who Paid My Doc
A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals
Research payments
$9,597,341
Through program year 2025, $9,597,341 in research payments was reported against A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals, across 615 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,104,289 | 79 |
| 2024 | Research | $4,382,026 | 310 |
| 2023 | Research | $4,111,026 | 226 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shelly Senders Cleveland, OH Named on 32 payments
- Jose Cardona Hialeah, FL Named on 30 payments
- Helen Stacey Walnut Creek, CA Named on 27 payments
- Veronica Fragoso Houston, TX Named on 27 payments
- Earl Martin Tomball, TX Named on 24 payments
- James Peterson Salt Lake City, UT Named on 22 payments
- Cindy Ta Honolulu, HI Named on 21 payments
- Daniel Finn Bardstown, KY Named on 20 payments
- Lisa Usdan Memphis, TN Named on 19 payments
- Salma Mazhar Mesquite, TX Named on 16 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.